Neuroscience Research - Alzheimer's Focus

Newmarket Scientific provides Antibodies, Proteins, Kits and related reagents for neuroscience research with a focus on Alzheimer's disease.

Some products are highlighted below, but many more are available, so please use the search box above to find specific reagents or email us at tech@nktscientific.com. 

Also for more information on neuroscience research in general, including highlighted articles/papers and other resources follow our Neuroscience Twitter feed NKTSciNeuro.

Alzheimer’s disease is a progressive neurodegenerative disease characterised by the aggregation of beta‐amyloid (amyloid β or Aβ) in extracellular plaques and hyperphosphorylated tau protein in intracellular neurofibrillary tangles (NFTs), however many other proteins have also been associated with Alzheimer’s disease pathology.

Newmarket Scientific provides antibodies to a large number of Alzheimer’s disease associated proteins and we continually monitor the latest publications in this area with the aim of identifying new and emerging potential targets to develop antibodies to, allowing us to better serve those at the forefront of Alzheimer’s disease research.

Some common targets for Alzheimer’s disease to which we have antibodies are listed below with a link to a more comprehensive list and more detailed information.

Amyloid beta   APP  Lipocalin 2  Nicastrin  Tau  TDP43  Tyrosine hydroxylase

...read more

Beautifully stain amyloid plaques in tissues in multi-labelling and low magnification studies

Histologic dyes commonly used for amyloid plaque detection such as Congo Red or Thioflavin S or T come with a number of limitations, including their broad excitation frequencies which cause "bleed through" when using filters for other stains and the need for harsh chemicals during staining making them less compatible with the subsequent use of antibodies.

Amylo-Glo RTD (Cat. No. TR-300-AG) is a histological marker that shows clear superiority for visualising amyloid plaques over conventional markers with its... read more

Brain-derived neurotrophic factor (BDNF) plays essential roles in the central nervous system regulating and supporting the growth, survival and differentiation of neurons. Brain insults or stress can cause variations in BDNF levels, which may contribute to depressive or neurological disorders such as epilepsy and Alzheimer’s disease.

To help researchers quantify BDNF, Biosensis have developed a robust ELISA for mature BDNF with high specificity that can be performed in less than 3 hours with high accuracy, sensitivity and reproducibility... read more and watch the video here.

The presence of aggregated amyloid-β peptides (Aβ) is a hallmark of Alzheimer's Disease. However, the forms of Aβ-peptides associated with this pathology remains unclear, in part because antibodies thought to be specific for Aβ were later shown to also detect intraneuronal amyloid precursor protein (APP) and not just Aβ.

Our Biosensis monoclonal antibody to Amyloid beta peptide (M-1586-100) is a new formulation of the MOAB-2 clone (also known as Clone 6C3) that does not cross react with APP. This new formulation provides clearer staining and greater sensitivity than formulations from other maufacturers and is also the only one endorsed by the original developers. Additionally, unlike... read more.

Brain cholesterol is an important membrane building component of glial cells, neurons and myelin sheaths. Unable to cross the blood-brain-barrier, cholesterol is synthesised in situ, transported between the various cells and eliminated via oxidative pathways to maintain appropriate levels.

Key to regulating brain cholesterol homeostasis the CNS-specific cytochrome P450 enzyme, cholesterol 24-hydroxylase (CYP46A1) is mostly expressed in the brain, converting excess cholesterol to membrane-permeable 24HC (oxysterol, 24S-hydroxycholesterol). This oxidised product diffuses through the blood-brain-barrier entering the systemic circulation to reach the liver where it is degraded to bile acids. Accumulation of cholest... read more and find out about our CYP46A1 antibodies.